EFFECT OF ZINC SUPPLEMENTATION ON ANTIDEPRESSANT THERAPY AND SERUM ZINC LEVEL IN UNIPOLAR DEPRESSION: A DOUBLE-BLIND RANDOMIZED CONTROLLED STUDY

Dr. Dileep Kumar Verma, Dr. Basudeb Das, Dr. Sourav Khanra

Abstract


Background: Recent studies have shown importance of zinc in pathogenesis of depression. However, literature on efficacy of adjunctive zinc supplementation for unipolar depression is conflicting.  Aims: The aim of our study was to assess effectiveness of adjunctive zinc in depression and to assess difference in serum zinc levels before and after treatment. Methods: Sixty drug naïve or drug free (for ≥2 weeks) subjects having diagnosis of unipolar depression (including recurrent depressive disorder) were recruited and allocated into two groups by simple random sampling. Both groups were assessed with HAM-D, BDI, BSSI and HAM-A. Subjects and raters were blinded to groups. Serum zinc level was assessed. Twenty milligrams of elemental zinc were given daily along with treatment as usual and the other group received treatment as usual only. Assessments were done at baseline and repeated at 2, 4 & 8 weeks. Results and conclusion: No significant difference was found between zinc group and treatment as usual group in reducing the severity of depressive symptoms. Our study concluded that adjunctive zinc supplementation along with antidepressants have no adjunctive effect on improvement in the severity of depression.


Keywords


zinc; depression; randomized; double blind

Full Text:

PDF

References


Hyman S, Chisholm D, Kessler R, Patel V, Whiteford H. Mental disorders, In: Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, et al. Editors. 2006. isease control priorities in developing countries, 2nd ed. New York. Oxford University Press; 2006: pp. 591–605.

Jenkins R, Lewis G, Bebbington, P, Brugha T, Farrell M, Gill B, et al,. The National Psychiatric Morbidity surveys of Great Britain–initial findings from the household survey. Psychol Med 1997;27: 775–89.

Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 2005;62: 617–27.

Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen. Psychiatry 1994;51: 8–19.

Robins LN, Helzer JE, Weissman MM, Orvaschel H, Gruenberg E, Burke JD, et al. Lifetime prevalence of specific psychiatric disorders in three sites. Arch. Gen. Psychiatry1984;41: 949–58.

Weissman MM, Leaf PJ, Tischler GL, Blazer DG, Karno M, Bruce ML, et al. Affective disorders in five United States communities. Psychol Med 1988; 18: 141–53.

Lee AS, Murray RM. The long-term outcome of Maudsley depressives. BrJPsychiatry 1988; 153: 741–51.

World Health Organization, 2001. The World Health Report — Mental Health New Understanding, New Hope. Geneva: WHO.

Greenberg, PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA, et al. 2001. The economic burden of depression in the United States: How did it change between 1990 and 2000? J. Clin. Psychiatry 2001; 64: 1465–75.

Thomas CM, Morris M. Cost of depression among adults in England in 2000. Br J Psychiatry 2003;183: 514–9.

Keller MB. The long-term treatment of depression. J Clin Psychiatry 1999;60 (Suppl 17): 41–5.

Fava M, Rush AJ. Current status of augmentation and combination treatments for major depressive disorder: A Literature review and a proposal for a novel approach to improve practice. Psychother Psychosom 2006;75: 139–53.

McLoughlinIJ, Hodge SJ. Zinc in depressive disorder. Acta Psychiatr Scand 1990;82: 451–3.

Maes M, D'Haese PC, Scharpe S, D'Hondt P, Cosyns P, De Broe ME, et al. Hypozincemia in depression. J. Affect. Disord. 31, 135–140

Nowak G, Siwek M, Dudek D, Zieba A, Pilc A. .Effect of zinc supplementation on antidepressant therapy in unipolar depression: A preliminary placebo-controlled study. PolJPharmacol 2003; 55: 1143–7.

Maes M, VandoolaegheE, Neels H, Demedts P, Wauters A, Meltzer HY, et al. Lower serum zinc in major depression is a sensitive marker of treatment resistance and of the immune/inflammatory response in that illness. Biol. Psychiatry 1997a; 42: 349–58.

Schlegel-Zawadzka M, Zieba A, Dudek D, Krosniak M, Szymaczek M, Nowak G. Effect of depression and of antidepressant therapy on serum zinc levels: A preliminary clinical study. In: Roussel AM, Anderson RA, Favrier AE, editors. Trace Elements in man and animals, 10. New York: Kluwer Academic Plenum Press; 2000: pp. 607–610.

Styczeń K. Sowa-Kućma M, Siwek M, Dudek D, Reszynski W, Szewczyk B, et al. The serum zinc concentration as a potential biological marker in patients with major depressive disorder. Metab Brain Dis 2017; 32: 97–103.

World Health Organization. The ICD-10 Classification of Mental and Behavioral Disorders, Diagnostic Criteria for Research, Geneva: WHO; 1993

Hamilton MA rating scale for depression. JNeurol Neurosurg Psychiatry 1960; 23: 56-62.

Beck AT, Ward C, Mendelson M. "Beck Depression Inventory (BDI)”. Arch. Gen. Psychiatry1961; 4: 561-71.

Beck AT, Weissman KM. Assessment of suicidal intention: The scale of suicidal ideation. J Consult Clin Psychol 1979; 47: 343-52.

Hamilton M. The Assessment of anxiety scales by rating. Br JMed Psychol1959;32: 50-55.

Castro M. Placebo versus Best-Available-Therapy Control Group in Clinical Trials for Pharmacologic Therapies Which Is Better? Proc Am Thorac Soc 2007;4(7): 570–73.

Enck P, Klosterhalfen S, Weimer K, Horing B, Zipfel S. The placebo response in clinical trials: more questions than answers. Philos Trans R SocLondB Biol 2011; Sci366(1572): 1889–95.

Szewczyk B, Brañski P, Wieroñska JM, Pałucha A, Pilc A, Nowak G. Interaction of zinc with antidepressants in the forced swimming test in mice. Pol JPharmacol 2002; 54: 681–5.

Cunha MP, Machado DG, Bettio LEB, Capra JC, Rodrigues ALS. Interaction of zinc with antidepressants in the tail suspension test. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1913–20.

Siwek M, Dudek D, Paul IA, Sowa-Kućma M, Zieba A, Popik P, et al. Zinc supplementation augments efficacy of imipramine in treatment resistant patients: A double blind, placebo-controlled study. J Affect Disord 2009; 118, 187–95.

Siwek M, Dudek D, Schlegel-Zawadzka M, Morawska A, Piekoszewski W, Opoka W, et al. Serum zinc level in depressed patients during zinc supplementation of imipramine treatment. J Affect Disord 2010; 126: 447–52.

Nguyen PH, Grajeda R, Melgar P, Marcinkevage J, Flores R, Martorell R. Weekly may be as efficacious as daily folic acid supplementation in improving folate status and lowering serum homocysteine concentration in Guatemalan women. J Nutr 2008; 138: 1491–8.

Nguyen PH, Grajeda R, Melgar P, Marcinkevage J, DiGirolamo AM, Flores R, et al. Micronutrient supplementation may reduce symptoms of depression in Guatemalan women. Arch Latinoam Nutr, 2009;59: 278–86.

Sawada T, Yokoi K. Effect of zinc supplementation on mood states in young women: A pilot study. Eur J Clin Nutr 2010;64: 331–3.

Lee IM, Cook NR, Gaziano JM, Gordon D, Ridker PM, Manson JE, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer. JAMA 2005; 294: 56–65.

Whittaker P. Iron and zinc interactions in humans. Am J Clin Nutr1998;68: 442S–6S.

Ranjbar E, SabetKasaei M, Shirazi MM, Nasrollahzadeh J, Rashidkhani B, Shams J, et al. Effects of zinc supplementation in patients with major depression: A Randomized Clinical Trial.Iran J Psychiatry 2013;8(2):73–9.

Maserejian NN, Hall SA, McKinlay JB. Low dietary or supplemental zinc is associated with depression symptoms among women, but not men, in a population-based epidemiological survey. J. Affect Disord 2012; 136: 781–8.

Szewczyk B, Poleszak E, Sowa-Kucma M, Siwek M, Dudek D, Ryszewska-Pokraśniewicz B, et al. Antidepressant activity of zinc and magnesium in view of the current hypotheses of antidepressant action. Pharmacol. Rep 2008; 60: 588–9.

Lehto SM, Ruusunen A, Tolmunen T, Voutilainen S, Tuomainen TP, Kauhanen J. Dietary zinc intake and the risk of depression in middle-aged men: A 20-year prospective follow-up study. JAffectDisord2013;150: 682–5.

Little KY, Castellanos X, Humphries LL, Austin J. Altered zinc metabolism in mood disorder patients. Biol Psychiatry 1989; 26: 646–8.

Styczeń K, Sowa-Kućma M, Siwek M, Dudek D, Reczyński W, Szewczyk B, et al. The serum zinc concentration as a potential biological marker in patients with major depressive disorder. Metab Brain Dis 2017; 32: 97–103.

Irmisch G, Schlaefke D, Richter J. Zinc and fatty acids in depression. Neurochem Res 2010; 35: 1376–83.

Narang RL, Gupta KR, Narang AP, Singh R. Levels of copper and zinc in depression. Indian J Physiol Pharmacol 1991; 35: 272–4.

Crayton JW, Walsh WJ. Elevated serum copper levels in women with a history of post-partum depression. J Trace Elem Med Biol 2007; 21: 17–21.

Gronli O, Kvamme JM, Friborg O, Wynn R. Zinc deficiency is common in several psychiatric disorders. PLoS One 2013;8:e82793).

Swardfager W, Herrmann N, Mazereeuw G, Goldberger K, Harimoto T, Lanctôt KL. Zinc in depression: A meta-analysis. Biol Psychiatry 2013; 74(12): 872-8.

Prasad AS. Clinical manifestations of zinc deficiency. Annu RevNutr1985; 5: 341–563.

Pilz S, Dobnig H, Winklhofer-Roob BM, Renner W, Seelhorst U, Wellnitz B, et al. Low serum zinc concentrations predict mortality in patients referred to coronary angiography. Br J Nutr 2009; 101: 1534–40.

Reunanen A, Knekt P, Marniemi J, Mäki J, Maatela J, Aromaa A. Serum calcium, magnesium, copper and zinc and risk of cardiovascular death. Eur. J ClinNutr 1996; 50: 431–7.

McClain CJ, Su LC. Zinc deficiency in the alcoholic: A review. Alcohol Clin Exp Res 1983; 7: 5–10


Refbacks

  • There are currently no refbacks.